At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 183 enrolled
Drug / intervention
Tezepelumab Dose 1 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria
In Brief
A Phase 2 clinical trial evaluating Tezepelumab Dose 1, Tezepelumab Dose 2, and 2 other interventions for Chronic Spontaneous Urticaria. Completed, enrolled 183 participants across 81 sites in 10 countries.
Detailed Summary
The primary objective of this study is to evaluate the effect of tezepelumab on improvement in the Urticaria Activity Score over 7 days (UAS7).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Spontaneous Urticaria
CountriesCanada, France, Germany, Greece, Italy, Japan, Poland, South Korea, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartApr 2021
Primary CompletionDec 2022
Study CompletionApr 2023
TodayJul 2026
First PostedApr 6, 2021
Enrollment StartApr 15, 2021
Primary CompletionDec 20, 2022
Study CompletionApr 13, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.2 years ago
Interventions
Tezepelumab Dose 1biological
Subcutaneous injection.
Tezepelumab Dose 2biological
Subcutaneous injection.
Omalizumabbiological
Subcutaneous injection.
Placebobiological
Subcutaneous injection.